Comparison of endoscopic healing and durability between infliximab originator and CT-P13 in pediatric patients with inflammatory bowel disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Eun Sil | - |
dc.contributor.author | Choi, Sujin | - |
dc.contributor.author | Choe, Byung-Ho | - |
dc.contributor.author | Park, Sowon | - |
dc.contributor.author | Lee, Yeoun Joo | - |
dc.contributor.author | Sohn, Sang Jun | - |
dc.contributor.author | Kim, Soon Chul | - |
dc.contributor.author | Kang, Ki Soo | - |
dc.contributor.author | Lee, Kunsong | - |
dc.contributor.author | Shim, Jung Ok | - |
dc.contributor.author | Kim, Yu Bin | - |
dc.contributor.author | Hong, Suk Jin | - |
dc.contributor.author | Lee, Yoo Min | - |
dc.contributor.author | Kim, Hyun Jin | - |
dc.contributor.author | Choi, So Yoon | - |
dc.contributor.author | Kim, Ju Young | - |
dc.contributor.author | Lee, Yoon | - |
dc.contributor.author | Park, Ji-Sook | - |
dc.contributor.author | Kim, Jae Young | - |
dc.contributor.author | Yi, Dae Yong | - |
dc.contributor.author | Lee, Ji Hyuk | - |
dc.contributor.author | Choi, Kwang-Hae | - |
dc.contributor.author | Jang, Hyo-Jeong | - |
dc.contributor.author | Jeong, In Sook | - |
dc.contributor.author | Kang, Ben | - |
dc.date.accessioned | 2024-06-12T01:31:48Z | - |
dc.date.available | 2024-06-12T01:31:48Z | - |
dc.date.issued | 2024-02 | - |
dc.identifier.issn | 1664-3224 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26322 | - |
dc.description.abstract | Background and aims: Favourable clinical data were published on the efficacy of CT-P13, the first biosimilar of infliximab (IFX), in pediatric inflammatory bowel disease (IBD); however, few studies have compared the effect on endoscopic healing (EH) and drug retention rate between the IFX originator and CT-P13. Therefore, we aimed to compare EH and the drug retention rate between the IFX originator and CT-P13. Methods: Children with Crohn's disease (CD) and ulcerative colitis (UC)/IBD-unclassified (IBD-U) at 22 medical centers were enrolled, with a retrospective review conducted at 1-year and last follow-up. Clinical remission, EH and drug retention rate were evaluated. Results: We studied 416 pediatric patients with IBD: 77.4% had CD and 22.6% had UC/IBD-U. Among them, 255 (61.3%) received the IFX originator and 161 (38.7%) received CT-P13. No statistically significant differences were found between the IFX originator and CT-P13 in terms of corticosteroid-free remission and adverse events. At 1-year follow-up, EH rates were comparable between them (CD: P=0.902, UC: P=0.860). The estimated cumulative cessation rates were not significantly different between the two groups. In patients with CD, the drug retention rates were 66.1% in the IFX originator and 71.6% in the CT-P13 group at the maximum follow-up period (P >0.05). In patients with UC, the drug retention rates were 49.8% in the IFX originator and 56.3% in the CT-P13 group at the maximum follow-up period (P >0.05). Conclusions: The IFX originator and CT-P13 demonstrated comparable therapeutic response including EH, clinical remission, drug retention rate and safety in pediatric IBD. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | FRONTIERS MEDIA SA | - |
dc.title | Comparison of endoscopic healing and durability between infliximab originator and CT-P13 in pediatric patients with inflammatory bowel disease | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3389/fimmu.2024.1284181 | - |
dc.identifier.scopusid | 2-s2.0-85186916972 | - |
dc.identifier.wosid | 001181937200001 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN IMMUNOLOGY, v.15 | - |
dc.citation.title | FRONTIERS IN IMMUNOLOGY | - |
dc.citation.volume | 15 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.subject.keywordPlus | NECROSIS FACTOR-ALPHA | - |
dc.subject.keywordPlus | CROHNS-DISEASE | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | BIOSIMILAR INFLIXIMAB | - |
dc.subject.keywordPlus | INNOVATOR INFLIXIMAB | - |
dc.subject.keywordPlus | MEDICAL-MANAGEMENT | - |
dc.subject.keywordPlus | PARALLEL-GROUP | - |
dc.subject.keywordPlus | CHILDREN | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordAuthor | children | - |
dc.subject.keywordAuthor | inflammatory bowel disease | - |
dc.subject.keywordAuthor | CT-P13 | - |
dc.subject.keywordAuthor | endoscopic healing | - |
dc.subject.keywordAuthor | durability | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.